Reasons why patients accept or decline clinical trials within the gastrointestinal team


Year:

Session type:

Theme:

Cyper Allan1,Sarah Brown1
1University of Sheffield

Abstract

Background

Over the last two decades some studies have attempted to examine the reasons for low recruitment uptake; Taylor (1987), Cook-Gotay (1991) and Fallowfield (1997) all agreed that strict eligibility trial criteria, lack of staff support and randomisation are the reasons. As there are no new studies available, this survey investigated the reasons why patients were accepting or declining entry to clinical trials.

Method

The survey utilized in this study was designed to provide some demographic data. Purposive sampling was employed in this survey. This sample type is also referred to as judgment, selective or subjective sampling is a non-probability sampling method that is characterised by a deliberate effort to gain representative samples by including groups or typical areas in a sample. The researcher relied on their judgment to select sample group members.

Results

The survey was carried out from November 2015 to February 2016 to all GI patients. 172 patients with GI cancer and eligible to participate in any clinical trials were invited to join the survey. Patients who were eligible comprised of newly diagnosed, already on treatment or on their follow-up. One hundred and twelve (65%) returned the questionnaires with SCOT (12.5%) and GI160 (12.5%) trial patients, STO3 (10.7%), FOxTROT (8.9%) and STO3 PET (8.9%) trial patients forming 53.5% of the total sample. Overall, 105/112 (94%) patients accepted entry to a clinical trial and 7/112 (6%) declined. The gender frequency distribution of all participants with male respondents (70%) outnumbered female patients (30%) who responded to the questionnaire survey.

Conclusion

Trust in the doctor and altruism are seen as the most important reasons for accepting entry to a trial. A total of 26 different kinds of trial were included in this survey and they are trials involving chemotherapy, standard or novel treatment, non-drug clinical trials involving blood samples and scanning of patients.